PMDD and Depression During the Menopausal Transition: New ... · •The majority of reproductive...
Transcript of PMDD and Depression During the Menopausal Transition: New ... · •The majority of reproductive...
www.mghcme.org
PMDD and Depression During the Menopausal Transition: New Insights
Laura Fagioli Petrillo, M.D.
Director of Training, The Ammon-Pinizzotto Center for
Women’s Mental Health, Massachusetts General
Hospital
Instructor in Psychiatry, Harvard Medical School
www.mghcme.org
Disclosures
Neither I nor my spouse/partner has a relevant financial relationship with a commercial interest to disclose.
www.mghcme.org
Depression and Anxiety Across the
Female Reproductive Cycle
Premenstrual depression/anxiety (eg,
PMDD)
Depression/anxiety
during pregnancy
Depression/anxiety during the
postpartum period
Menarche Menopause
Pregnancy
Depression/anxiety associated with infertility, miscarriage, or perinatal
loss
Depression/anxiety during the
perimenopausal period
www.mghcme.org
Premenstrual Mood Changes
• The majority of reproductive age women report unpleasant symptoms around the time of menstruation.
– Physical and psychological symptoms
– “More emotional”
– Minimal effect on functioning
Winer & Rapkin, Jnl Reproductive Med. 2006:51(4): 339-347.
www.mghcme.org
Prevalence of Premenstrual Conditions
PMS75%
Nothing20%
PMDD5%
(3-8% of women of childbearing age)
100%=all women of childbearing age.
Haskett RF. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(2-3):129-135.Johnson SR, et al. J Reprod Med. 1988;33(4):340-346.Rivera-Tovar AD, Frank E. Am J Psychiatry. 1990;147(12):1634-1636.Ramcharan S, et al. J Clin Epidemiol. 1992;45(4):377-392.
www.mghcme.org
Premenstrual Syndrome (PMS)
• Pattern of physical, emotional and behavioral symptoms occurring 1-2 weeks before menstruation
• Remit with the onset of menstruation
• 30-80% of women
• Significant in 3-8% of women
www.mghcme.org
PMS Symptoms
Psychological
Symptoms
Behavioral
Symptoms
Physical
Symptoms
www.mghcme.org
PMDD - DSM-V Criteria
• Criterion A: in most menstrual cycles during the past year, at least 5 of 11 symptoms (including at least 1 of the first 4 listed) were present:
• Markedly depressed mood, hopelessness, or self-deprecating thoughts • Marked anxiety, tension, feelings of being “keyed up” or “on edge” • Marked affective lability • Persistent/marked anger or irritability or interpersonal conflicts • Decreased interest in usual activities • Subjective sense of difficulty in concentrating • Lethargy, easy fatigability, or marked lack of energy • Marked change in appetite, overeating, or specific food cravings • Hypersomnia or insomnia • A subjective sense of being overwhelmed or out of control • Other physical symptoms, such as breast tenderness or swelling, headaches, joint
or muscle pain, a sensation of bloating, or weight gain • The symptoms must have been present for most of the time during the last week
of the luteal phase, begun to remit within a few days of the onset of menstrual flow, and absent in the week after menses.
www.mghcme.org
DSM-V Criteria
• Criterion B is that the symptoms must be severe enough to interfere significantly with social, occupational, sexual, or scholastic functioning.
• Criterion C is that the symptoms must be discretely related to the menstrual cycle and must not merely represent an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, dysthymic disorder, or a personality disorder
• Criterion D is that criteria A, B, and C must be confirmed by prospective daily ratings during at least 2 consecutive symptomatic menstrual cycles. The diagnosis may be made provisionally before this confirmation.
www.mghcme.org
Premenstrual Exacerbation (PME)
• Mood disorders can worsen premenstrually
• PMDD vs. PME
• 40% of women screened for PMDD have an underlying mood disorder with PME
• Charting to determine cyclicity of symptoms
Bailey & Cohen. J Womens Health Gender Based Med. 1999;8(9):1181.
www.mghcme.org
0
1
2
3
4
Sym
pto
m S
ever
ity
Menses Ovulation Menses
PME
PMDD
PMDD vs. Premenstrual Exacerbation (PME)
www.mghcme.org
Prospective Rating for Patient With PMS
www.mghcme.org
Prospective Rating for Patient With PMDD
www.mghcme.org
Prospective Rating for Patient With Depression
www.mghcme.org
www.mghcme.org
Pathophysiology
• No clear evidence of “hormonal dysregulation”
• PMS/PMDD may represent an abnormal response to normal fluctuations of gonadal steroids
Schmidt et al., American Journal of Psychiatry:2017;174(10), 980-989.
www.mghcme.org
Differential sensitivityto normal changes in estrogen andprogesterone
GnRH agonists areeffective therapy
• Eliminate hormonal fluctuation
• PMS re-occurs withadd-back therapy
GnRH = gonadotropin-releasing hormone.
Schmidt et al. N Engl J Med. 1998;338:209.
Hormonal Basis of PMDD
www.mghcme.org
Hormonal Basis of PMDD
Schmidt PJ, Martinez PE, Nieman LK, et al. Am J Psychiatry. 2017;174:980-989.
www.mghcme.org
Pathophysiology
ESTROGEN PROGESTERONE
CENTRAL NEUROTRANSMISSION
SEROTONERGIC/NORADRENERGIC/DOPAMINERGIC
SEROTONIN TRANSMISSION ABNORMALITY PMDD
www.mghcme.org
Pathophysiology
Role of gamma amino-butyric acid (GABA)
Allopregnanolone enhances effects of GABA
-Metabolite of progesterone
-Positive modulator of GABAA receptor
Treatment with allopregnanolone antagonist during the luteal phase reduced PMDD scores on the DRSP.
Bixo et al. Psychoneuroendocrinology:2017;80:46-55.
www.mghcme.org
PMS/PMDD Longitudinal Course
– Women seek treatment in their late 20s/early 30s
– Peaks around 30-39 years old1
– Physical/mood symptoms stable from cycle to cycle2
– Diagnosis appears stable over time3
– Chronic course; symptoms may worsen over time [with age4, pregnancy5]
1Johnson. Clin Obstet Gynecol. 1987;30:369.2Block. Am J Psychiat. 1997;154:1741. 3Roca et al. J Clin Psychiatry. 1999;60:763.
4Ramcharan. J Clin Epidemiol. 1992;45:377. 5Campbell. J Reprod Med. 1997;42:637.
www.mghcme.org
1. van den Akker OB, et al. Acta Genet Med Gemellol (Roma ). 1987;36(4):541-548. 2. Kendler KS, et al. Psychol Med. 1992;22(1):85-100. 3. Warner P, et al. J Affect Disord. 1991;23(1):9-23. 4. Bancroft J, et al. Psychosom Med. 1994;56(3):225-231. 5. Graze KK, et al. Acta Psychiatr Scand. 1990;81(2):201-205.
Risk Factors for PMDD and PMS
• Family history of PMS and PMDD1,2
• History of postpartum depression3
• Major depression past3,4 or future5
• Mood changes induced by oral contraceptives
www.mghcme.org
Pharmacologic Treatment
SSRIs are first line treatment– Low dose– Rapid response– Fluoxetine, sertraline, and controlled release paroxetine
are FDA approved
Antidepressants with serotonergic activity are also effective:
clomipraminevenlafaxineduloxetine
Sundblad et al. Acta Psychiatr Scand. 1992;85:39-47.Freeman et al. Obstet Gynecol. 2001;98:737-44.Ramos & Hara. Int J Neuropsychopharmacol. 2009;12(8):1081-8.
www.mghcme.org
Antidepressant Dosing
• Continuous
– Steady dose throughout the month
• Intermittent
– Luteal phase
• Luteal phase increase
– Continuous with luteal phase “bump up”
www.mghcme.org
Who is a Candidate for Intermittent Treatment?
• Women who have premenstrual symptoms that require pharmacologic treatment
• Women without additional psychiatric co-morbidity that would require daily treatment
• Women with fairly regular menstrual cycles who can estimate when to initiate treatment
www.mghcme.org
1.de la Gandara Martin JJ. Actas Luso Esp Neurol Psiquiatr Cienc Afines.1997;25(4):235-242. 2. Pearlstein TB, Stone AB. J Clin Psychiatry. 1994;55(8):332-335.3. Elks ML. South Med J. 1993;86(5):503-507. 4. Yonkers KA. Psychopharmacol Bull. 1998;34(3):261-266. 5. Freeman EW, et al. Am J Psychiatry. 1992;149(4):531-533.
Duration of Treatment in PMDD
• Many women relapse when they stop treatment–as early as 1 to 2 cycles1-5
• Well tolerated and efficacious when used longer than 6 months in open-label studies1-3
• Patients should be reevaluated regularly
– Chronic treatment may be necessary
www.mghcme.org
Oral Contraceptives (OC)and PMS/PMDD
Evidence from double-blind, randomized, placebo-controlled trials supports use of some OCs for treatment of PMDD.
OCs containing drosperinone may be more effective.
• derivative of spironolactone versus testosterone derived progestins
www.mghcme.org
OCP Dosing
• Cyclic
– 21 days active pill, 7 days placebo
• Continuous
– Consecutive pill packs without a placebo
– Efficacy greater than cyclic dosing
Consider: medical risks of OCP
OCP can increase suicide risk
Freeman et al. Contraception. 2012;85(5): 437-445Skovlund et al. Am Jnl Psychiatry. 2018;175(4): 336-342
www.mghcme.org
Mortola JF et al. J Clin Endocrinol Metab. 1991; 72: 252A–252F. Ripps BA et al. J Reprod Med. 2003;48:761–766. Wyatt et al. Br J Obstet Gynaecol. 2004; 111: 585-593
Gonadotropin-ReleasingHormone Agonists for PMDD
Leuprolide/buserelin
Down-regulate gonadotrophin receptors in pituitary to create a hypogonadotropic state
Induce a reversible medical menopause
Administered by nasal spray or subcutaneously
Treatment usually restricted to six months
www.mghcme.org
• Side effects: hot flashes, vaginal dryness, osteoporosis
• Add-back estrogen and progesterone may reduce the effectiveness of the GnRH agonist treatment of PMS due to the induction of mood and anxiety symptoms
Gonadotropin-ReleasingHormone Agonists
www.mghcme.org
1. Brown CS, et al. Obstet Gynecol. 1994;84(5):779-786. 2. Freeman EW, et al. Psychopharmacol Bull. 1997;33(2):303-309. 3. Hammarback S, Backstrom T. Acta Obstet Gynecol Scand. 1988;67(2):159-166. 4. Hussain SY, et al. Gynecol Endocrinol. 1992;6(1):57-64. 5. Leather AT, et al. Gynecol Endocrinol. 1999;13(1):48-55. 6. Muse KN, et al. N Engl J Med. 1984;311(21):1345-1349. 7. Schmidt PJ, et al. N Engl J Med. 1998;338(4):209-216. 8. Sundstrom I, et al. Acta Obstet Gynecol Scand. 1999;78(10):891-899. 9. Helvacioglu A, et al. J Reprod Med. 1993;38(11):864-870. 10. West CP, Hillier H. Hum Reprod. 1994;9(6):1058-1063.
Gonadotropin-ReleasingHormone Agonists
• Double-Blind, placebo-controlled trials
– Several show superiority of GnRH agonists over placebo1–8
– Some show GnRH agonists equal to placebo9,10
– Not first line
www.mghcme.org
Non-Pharmacologic Treatment
• Mood Charting
• Lifestyle Modification
• Psychotherapy
• Nutritional Supplements
• CAM
Andrzej, M & Diana, J. Maturitas. 2006;55:S47-S54.
www.mghcme.org
Nutritional Supplements
Calcium (1200 mg daily)
Vitamin B6 (50-100 mg daily)
Magnesium (200-460 mg daily)
Vitamin E (400 IU daily)
Thys-Jacobs S et al. Am J Obstet Gynecol. 1998;179: 444–52. Chocano-Bedoya P et al. The Am Jnl Clin Nutr. 2011;93(5):1080-1086. Fathizadeh N et al. Iran J Nurs Midwifery Res. 2010;15:401-5.
www.mghcme.org
Herbal Remedies
• Vitex Agnus Castus (Chasteberry)– Association of Reproductive Health Professionals
includes VAC as a treatment option– Data are inconclusive– Potential benefits– Unclear mechanism: D2 receptor, estrogen receptor
• St. John’s Wort– Physical symptoms > emotional symptoms– 13-15% reduction in the level of OCP
Cerqueira RO, et al. Arch Womens Ment Health. 2017;20:713-719.Verkaik S, et al. Am J Obstet Gynecol. 2017;217:150-166Jang SH, et al. BMC Complement Altern Med. 2014;14:11.
www.mghcme.org
Summary
• Premenstrual symptoms are common.
• A smaller percentage of women experience severe physical and emotional symptoms that interfere with their ability to function.
• Screening for these symptoms is important as it may lead to treatments that can be beneficial.
• Treatments can be non-pharmacologic or pharmacologic.
– Hormonal or psychotropic
www.mghcme.org
What is Menopause?
• 12 months without menses
• Menopausal transition– endocrinologic, somatic, psychological changes
• Average age is 51 (lower for smokers)
• Severity, frequency and variety of symptoms vary widely
• Perimenopause = passage from reproductive to non-reproductive life
www.mghcme.org
MENOPAUSAL TRANSITION
Longo et al. Harrison’s Principles of Internal Medicine, 18th edition.
www.mghcme.org
Symptoms
• Hot flashes
• Vaginal dryness
• Depression/anxiety
• Osteopenia/osteoporosis
• Sleep changes
• Fatigue
• Concentration difficulty
www.mghcme.org
Hot Flashes
Sensation of warmth of the upper bodyLast 30 seconds – 5 minutesAccompanied palpitations, anxiety, dizzinessMay result in a cold sensation and/or chillsDaytime and/or nightCan occur from perimenopause through post menopause45-85% of women
Severe in 10-15% of womenAssociated sleep disruption
www.mghcme.org
Hot Flashes
• Natural menopause
– Vasomotor symptoms decrease over a few years
• Surgical menopause
– Severe vasomotor symptoms post-surgery
www.mghcme.org
Depression-Risks
• History of depression
– Women without lifetime MDD = lower risk of developing MDD during midlife vs women with prior MDD (28% v. 59%)
• History of postpartum depression
• Higher BMI
• Vasomotor symptoms
• Surgical menopause
• Estrogen itself may also have an antidepressant as well as a direct sleep effect
Eichling, P.S. and Sahni, J. J Clin Sleep Med. 2005;1(3), 291-300. Bromberger, JT, et al. Psychol
Med. 2015;45:1653-64. Georgakis MK, et al. JAMA Psychiatr. 2016;6:1-12.
www.mghcme.org
Depression
Meta-analysis of 14 observational studiesLower likelihood of postmenopausal depression with longer duration of reproductive age
– Age at menopause minus age at menarche
Premature menopause associated with higher rates of depression
Georgakis MK. JAMA Psychiatry. 2016;73:139-149.
www.mghcme.org
Sleep
• Sleep disruption is the hallmark of menopause• Nighttime vasomotor symptoms correlate with increased
sleep fragmentation– Depression is more common in this group
• Sleep disordered breathing more common during menopause (weight gain, unknown endocrine reasons)
• Also increase in fibromyalgia and insomnia/depression• Menopausal sleep disruption can exacerbate other
conditions, i.e. circadian disorders and RLS
.Joffe H, Crawford S, Economu N, Kim S, Regan S, Jalle JE, White D. Sleep. 2013 Dec 1;36(12):1977-85. doi:
10.5665/sleep.3244. Eichling, P.S. and Sahni, J. J Clin Sleep Med. 2005:1(3), pp.291-300
www.mghcme.org
Treatment
• Hormone replacement therapy
• Antidepressants
• Other psychotropics
• Complementary and alternative medications
• Non-pharmacologic treatment
www.mghcme.org
Hormone Replacement Therapy
• Gold standard until late 1990s
• Results from WHI changed practice
– Higher rates of CVA, coronary artery disease, breast cancer
– Worsening cognition
– Benefit: colorectal cancer and endometrial cancer
– Average age mid-60s
www.mghcme.org
HRT and Depression
• Rates of depression double to triple in the menopausal transition compare to pre and late menopause
• Estrogen +/- progesterone may alleviate depression
– Eliminate fluctuations in estrogen levels
Bromberger et al. Psychol Med. 2011;4:1879-88. Gleason et al. PLoS Med. 2015;12(6):e1001833.Joffe at al. J Clin Endocrinol Metab. 2011;96(7):E1044-E1054.
www.mghcme.org
HRT and Depression
• Estrogen replacement may be effective in preventing depression during the menopausal transition
• RTC of 172 perimenopausal and early postmenopausal women
• Transdermal estrogen + intermittent micronized progesterone vs. placebo
• Hormone therapy reduced the risk for depression by half
Gordon et al. JAMA Psychiatry. 2018;75(2):149-157.
www.mghcme.org
HRT and Mortality
• 27,000 postmenopausal women
• HRT with conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) median of 5.6 years
• or with CEE alone for a median of 7.2 years
• No increased risk of all-cause, cardiovascular, or cancer mortality– Did not prevent CV disease, other chronic diseases, or
reduce mortality
Manson JE, et al. JAMA. 2017;318:927-938.
www.mghcme.org
Antidepressants
• SSRIs/SNRIs – helpful
• Depression and vasomotor symptoms
– Paroxetine is FDA approved for hot flashes
– Fluoxetine, escitalopram, venlafaxine also helpful
www.mghcme.org
Antidepressants and Fractures
• Antidepressants linked to bone loss in the past
• Women with higher anxiety levels had a greater number of fractures over 10 years
• 192 postmenopausal women, avg. age 68
• 20% of women with lowest anxiety levels had a fracture vs 25% of those with highest anxiety– Higher anxiety associated with lower bone mineral density
in the lumbar spine and femoral neck
Catalano A, et al. Menopause. 2018
www.mghcme.org
Other Psychotropics
• Gabapentin
– Improvement in sleep and hot flashes
– Dose 100-3600 mg
• Sleep meds
– Zolpidem, eszopiclone improve sleep and hot flashes. ? Low dose TCAs (e.g. doxepin)
• Clonidine– Improves hot flashes
• Armodafinil
– Improves fatigue
www.mghcme.org
CAM
• Black cohosh – limited data, mixed results
• Omega-3 – improvement in hot flashes
• Soy – mixed results; significant placebo response
Mintziori G, Lambrinoudaki I, Goulis DG, et al. Maturitas. 2015
www.mghcme.org
Non-pharmacologic
• CBT
• Yoga
• Exercise
www.mghcme.org
CBT
CBT-Meno
psychoeducation
cognitive behavioral strategies VMS
depressive symptoms
anxiety
sleep
sexual concerns
Improvement sustained at 3 months post-treatment
Green et al. Menopause.2019;9:972-80.
www.mghcme.org
Effect of CBT on Sleep
Guthrie et al. Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. Sleep, 2018:41.
Sleep disturbance is a common among peri- and post-menopausal women7 interventions for sleep were assessed as part of MS-FLASH, RTCs for insomnia
www.mghcme.org
Yoga and Hot Flashes
• Meta-analysis, of 13 RTCs with a total of 1306 participants
• Improvements in psychological, somatic, vasomotor, and urogenital symptoms
Cramer H, Peng w, Lauche R. Maturitas, March 2018
www.mghcme.org
Summary
• It is important to identify mood symptoms during the menopausal transition
• Menopausal symptoms other than mood (sleep, vasomotor) can significantly affect quality of life
• Symptoms are treatable with pharmacologic and non-pharmacologic interventions